PE20151949A1 - Composiciones y metodos para producir cetosis elevada y sostenida - Google Patents

Composiciones y metodos para producir cetosis elevada y sostenida

Info

Publication number
PE20151949A1
PE20151949A1 PE2015002047A PE2015002047A PE20151949A1 PE 20151949 A1 PE20151949 A1 PE 20151949A1 PE 2015002047 A PE2015002047 A PE 2015002047A PE 2015002047 A PE2015002047 A PE 2015002047A PE 20151949 A1 PE20151949 A1 PE 20151949A1
Authority
PE
Peru
Prior art keywords
ketosis
blood
medium chain
restriction
compositions
Prior art date
Application number
PE2015002047A
Other languages
English (en)
Inventor
Patrick Arnold
Shannon Kesl
Agostino Dominic Paul D
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151949(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of PE20151949A1 publication Critical patent/PE20151949A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a las sales minerales de beta-hidroxibutirato en combinacion con acidos grasos de cadena media o un ester de los mismos tales como trigliceridos de cadena media, se utilizaron para inducir cetosis, alcanzando niveles de cetona en sangre de (2-7 mmol/L), con o sin restriccion alimenticia. La combinacion da por resultado en mejoras sustanciales en los biomarcadores metabolicos con relacion a la resistencia a insulina, diabetes, perdida de peso y desempeno fisico en un periodo de tiempo corto. Ademas, el uso de estos suplementos para alcanzar la cetosis proporciona una elevacion significativa de cetonas en sangre y la reduccion de niveles de glucosa en sangre. El uso de estas sustancias no afecta adversamente los perfiles lipidicos. Al iniciar una cetosis rapida y al acelerar la velocidad de ceto-adaptacion, esta invencion es util para evitar los sintomas de retiro de glucosa experimentados comunmente por individuos que inician una dieta cetogenica, y reduce al minimo la perdida de masa corporal magra durante una restriccion alimenticia
PE2015002047A 2013-03-19 2014-03-19 Composiciones y metodos para producir cetosis elevada y sostenida PE20151949A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361803203P 2013-03-19 2013-03-19
US201461926664P 2014-01-13 2014-01-13

Publications (1)

Publication Number Publication Date
PE20151949A1 true PE20151949A1 (es) 2016-01-05

Family

ID=51581503

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002047A PE20151949A1 (es) 2013-03-19 2014-03-19 Composiciones y metodos para producir cetosis elevada y sostenida

Country Status (21)

Country Link
US (4) US9138420B2 (es)
EP (1) EP2976073B1 (es)
JP (2) JP6491189B2 (es)
KR (2) KR102499654B1 (es)
CN (1) CN105050594B (es)
AU (2) AU2014236004B2 (es)
BR (1) BR112015024186B1 (es)
CA (1) CA2902603C (es)
CL (2) CL2015002802A1 (es)
CR (1) CR20150579A (es)
HK (1) HK1216847A1 (es)
IL (2) IL241316B (es)
MX (2) MX371259B (es)
MY (1) MY180761A (es)
NZ (1) NZ711433A (es)
PE (1) PE20151949A1 (es)
PH (1) PH12015501966B1 (es)
RU (2) RU2018120938A (es)
SG (2) SG10201808690PA (es)
WO (1) WO2014153416A1 (es)
ZA (1) ZA201506387B (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108740A2 (en) 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
EP3659595A1 (en) 2012-11-05 2020-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
EP2968260B1 (en) 2013-03-14 2020-12-16 University of Florida Research Foundation, Inc. Regulation of cancer using natural compounds and/or diet
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
EP3125904A4 (en) * 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
AU2016283408A1 (en) * 2015-06-26 2018-01-04 University Of Florida Research Foundation, Incorporated Method of treating inflammation using natural compounds and/or diet
US10987340B2 (en) 2015-07-24 2021-04-27 Jesse Alexander Galinski Composition and method for rapidly inducing an endogenous ketosis
US10292952B2 (en) * 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) * 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US20170266147A1 (en) * 2016-03-18 2017-09-21 Csilla Ari D'Agostino Methods of increasing latency of anesthetic induction using ketone supplementation
WO2017165443A1 (en) * 2016-03-21 2017-09-28 Csilla Ari D'agostino Methods of improving motor function using ketone supplementation
WO2017165445A1 (en) * 2016-03-21 2017-09-28 Csilla Ari D'agostino Administration of exogenous ketone to lower blood glucose
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
WO2017184788A1 (en) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
SG11201809221WA (en) * 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of berberine metabolites
US11337945B2 (en) 2016-06-01 2022-05-24 Keto Innovations, Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
CN109477993B (zh) 2016-06-07 2023-03-28 J大卫格莱斯顿研究机构 β-羟基丁酸酯和丁二醇的中链脂肪酸酯和组合物及其使用方法
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
JP6935994B2 (ja) 2016-08-19 2021-09-15 株式会社明治 ケトン体生成促進用組成物
US20180057846A1 (en) * 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US11297873B2 (en) 2016-09-13 2022-04-12 Abbott Laboratories Ketogenic nutritional compositions
US10945975B2 (en) * 2016-10-24 2021-03-16 University Of South Florida Delaying latency to seizure by combinations of ketone supplements
US20180177753A1 (en) * 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
ES2942748T3 (es) * 2017-03-08 2023-06-06 Abbott Diabetes Care Inc Sistema para la supervisión y gestión del bienestar y la nutrición utilizando datos de analito
JP6951421B2 (ja) * 2017-03-28 2021-10-20 ロンザ・ソリューションズ・アー・ゲー 水溶性抗菌組成物
JP6968624B2 (ja) * 2017-04-06 2021-11-17 株式会社明治 ケトン食摂取量の管理方法
US11249087B2 (en) 2017-04-06 2022-02-15 Meiji Co., Ltd. Device for monitoring effective state of ketogenic diet
WO2018187852A1 (en) * 2017-04-12 2018-10-18 Cavaleri Franco Butyrate and beta-hydroxybutyrate compositions and methods of use thereof
CN107083406B (zh) * 2017-05-27 2021-02-02 浙江华睿生物技术有限公司 (r)-3-羟基丁酸的生产方法
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
JP7442095B2 (ja) 2017-07-21 2024-03-04 バック・インスティテュート・フォー・リサーチ・オン・エイジング ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法
CN109394745A (zh) * 2017-08-17 2019-03-01 博瑞生物医药（苏州）股份有限公司 一种包含左旋肉碱和β-羟基丁酸化合物的组合物
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US20190119705A1 (en) * 2017-10-20 2019-04-25 KetoneAid Inc. Substantially non-racemic ketone ester of beta hydroxybutyrate and production process thereof
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) * 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11596616B2 (en) 2017-12-12 2023-03-07 University Of South Florida Compositions and methods for weight loss maintenance
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
CN112105352A (zh) * 2018-01-05 2020-12-18 得克萨斯理工大学研究商业化办公室 与间歇性禁食相关的β-羟基-β-甲基丁酸(HMB)组合物和使用方法
BR112020013342A2 (pt) * 2018-02-01 2020-12-01 Wellstat Therapeutics Corporation composições e dispositivos para fornecimento sistêmico de uridina
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en) * 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US20200061023A1 (en) * 2018-08-27 2020-02-27 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11484542B2 (en) 2018-05-30 2022-11-01 Adam Slank Specialized tongue spray containing gymnemic acid and exogenous ketones
US20190373917A1 (en) * 2018-06-07 2019-12-12 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
CA3022995C (en) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Novel ketogenic compounds, compositions, methods and use thereof
US20210267251A1 (en) * 2018-06-21 2021-09-02 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor
EP3843716A4 (en) * 2018-08-27 2022-06-01 Exerkine Corporation LYSOSOMAL DISEASE TREATMENT METHOD
US20200068939A1 (en) * 2018-09-04 2020-03-05 Jho Intellectual Property Holdings Llc Nutritional compositions to increase and sustain blood ketone levels
CA3112205A1 (en) 2018-09-25 2020-04-02 Ponce De Leon Health Designated Activity Company Process for making calcium alpha-ketoglutarate
WO2020073033A1 (en) * 2018-10-05 2020-04-09 Ampersand Biopharmaceuticals, Inc. Formulations and methods for transdermal administration of ketones
CA3118317A1 (en) * 2018-10-29 2020-05-07 Keto Patent Group, Inc. Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans
CN109480284A (zh) * 2018-12-05 2019-03-19 上海欣海生物科技有限公司 一种生酮食品及其制备方法
EP3897178A1 (en) * 2018-12-18 2021-10-27 Société des Produits Nestlé S.A. Mixed triglyceriges
CN109734575A (zh) * 2019-01-04 2019-05-10 上海欣海国际贸易有限公司 一种制备3-羟基丁酸氨基酸盐复合物的方法
CN113660930A (zh) * 2019-02-11 2021-11-16 阿克塞斯全球科学有限责任公司 β-羟基丁酸盐混合盐-酸组合物和使用方法
AU2020221916A1 (en) * 2019-02-11 2021-09-02 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
CA3129541A1 (en) * 2019-02-11 2020-08-20 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
AU2020235643A1 (en) * 2019-03-14 2021-09-30 Augusta University Research Institute, Inc. Methods and compositions for supporting renal health
JP7281927B2 (ja) * 2019-03-14 2023-05-26 大阪瓦斯株式会社 心拍数低減剤
US20220168256A1 (en) * 2019-03-22 2022-06-02 Societe Des Produits Nestle S.A Methods using administration of medium chain triglycerides (mct) prior to a meal to increase ketone production from the mcts
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
BR112021025043A2 (pt) * 2019-06-12 2022-02-01 Ioi Oleo Gmbh Processo para a produção de ácidos 3-hidroxicarboxílicos capeados com acila assim como seus sais e ésteres
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11915605B2 (en) 2019-10-17 2024-02-27 Nicolas Tzenios Ketogenic diet recommendation to a user based on a blood low-density lipoprotein (LDL) level and a blood C-reactive protein level and/or a blood erythrocyte sedimentation rate (ESR) thereof
US20230172891A1 (en) * 2020-01-23 2023-06-08 University Of South Florida Prevention and treatment of effects of aging and age-associated disorders with ketone supplementation
EP4114203A1 (en) 2020-03-05 2023-01-11 VitaNav, Inc. COMPOSITION OF (D)-ß-HYDROXYBUTYRIC ACID, (D)-ß-HYDROXYVALERIC ACID, AND (D)-1,3 BUTANEDIOL AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENT
EP4164407A1 (en) * 2020-06-14 2023-04-19 L-Nutra Inc. An intermittent fasting bar/drink that maintains and extends the fasting state
EP4175978A1 (en) * 2020-07-02 2023-05-10 Ponce de Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases
US20220062216A1 (en) * 2020-08-26 2022-03-03 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN112137115A (zh) * 2020-09-25 2020-12-29 深圳市捷利康生物科技有限公司 具有增强免疫力功效的生酮营养粉及其制备方法
WO2022140279A1 (en) * 2020-12-22 2022-06-30 Buck Institute For Research On Aging Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies
WO2022232106A1 (en) * 2021-04-26 2022-11-03 University Of South Florida Methods for treating symptoms of kabuki syndrome
RU2769242C1 (ru) * 2021-06-16 2022-03-29 Александр Владимирович Чемоданов Кетогенная композиция
WO2023278240A1 (en) 2021-06-28 2023-01-05 Phb Industrial S.A. Methods to produce therapeutic formulations comprising hydroxybutirate and hydroxyvalerate, therapeutic formulations and uses thereof
WO2023112817A1 (ja) * 2021-12-14 2023-06-22 サントリーホールディングス株式会社 ３ヒドロキシ酪酸及び低級脂肪族アルコールを含有する飲料及び呈味改善方法
WO2023112818A1 (ja) * 2021-12-14 2023-06-22 サントリーホールディングス株式会社 炭酸飲料及び炭酸飲料の炭酸感を増強する方法
CN114306308A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有酮酯的营养补充剂及其应用
WO2023139357A1 (en) * 2022-01-18 2023-07-27 Today Inc. Molecules, nutritional formulations, and methods of providing nutritional support
JP7223193B1 (ja) 2022-05-26 2023-02-15 大阪瓦斯株式会社 内臓脂肪低減剤およびその用途
CN115192603B (zh) * 2022-07-06 2023-04-21 西北农林科技大学 锂盐在制备防治奶牛酮病制剂中的应用
CN115251375A (zh) * 2022-07-11 2022-11-01 珠海麦得发生物科技股份有限公司 一种(r)-3-羟基丁酸生酮产品及其制备方法
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8803141L (sv) * 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
AU749638B2 (en) * 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
JPH1160434A (ja) 1997-08-12 1999-03-02 Kanebo Ltd 皮膚老化防止化粧料
ATE283056T1 (de) * 1998-07-22 2004-12-15 Metabolix Inc Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere
NZ509739A (en) 1998-09-15 2003-10-31 Btg Int Ltd A cyclic ester of (R)-3-hydroxybutyrate useful for increasing cardiac efficiency
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DE60138019D1 (de) 2000-05-01 2009-04-30 Accera Inc Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
US6613356B1 (en) 2000-10-10 2003-09-02 Victor Vlahakos Weight loss medication and method
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US8158184B2 (en) * 2004-03-08 2012-04-17 Bunge Oils, Inc. Structured lipid containing compositions and methods with health and nutrition promoting characteristics
GB0410266D0 (en) * 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
EP2468273A3 (en) * 2005-06-20 2012-07-11 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
HUE040002T2 (hu) * 2006-04-03 2019-02-28 Accera Inc Ketogén vegyületek alkalmazása korfüggõ memóriazavar kezelésére
WO2008005818A1 (en) 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
JP2010523714A (ja) * 2007-04-12 2010-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 虚血／再灌流保護組成物および使用法
CN101969769A (zh) * 2008-01-04 2011-02-09 伊希斯创新有限公司 用作降低血脂药剂的酮体和酮体酯
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output

Also Published As

Publication number Publication date
RU2018120938A (ru) 2018-11-06
PH12015501966A1 (en) 2016-01-11
HK1216847A1 (zh) 2016-12-09
CL2018000983A1 (es) 2018-10-12
RU2659386C2 (ru) 2018-06-29
CA2902603C (en) 2021-03-02
EP2976073A4 (en) 2017-02-22
EP2976073A1 (en) 2016-01-27
RU2018120938A3 (es) 2019-04-04
US10646462B2 (en) 2020-05-12
CN105050594B (zh) 2019-11-12
IL241316B (en) 2018-08-30
US20160067207A1 (en) 2016-03-10
KR20220011785A (ko) 2022-01-28
US20170266148A1 (en) 2017-09-21
JP6491189B2 (ja) 2019-03-27
PH12015501966B1 (en) 2016-01-11
CA2902603A1 (en) 2014-09-25
CR20150579A (es) 2016-01-04
CN105050594A (zh) 2015-11-11
US20140350105A1 (en) 2014-11-27
AU2014236004B2 (en) 2018-10-25
ZA201506387B (en) 2017-08-30
JP2019031578A (ja) 2019-02-28
JP2016514725A (ja) 2016-05-23
US9138420B2 (en) 2015-09-22
NZ711433A (en) 2017-03-31
MY180761A (en) 2020-12-08
SG10201808690PA (en) 2018-11-29
RU2015136190A (ru) 2017-03-10
KR20150130312A (ko) 2015-11-23
CL2015002802A1 (es) 2016-05-06
AU2019200511A1 (en) 2019-02-14
US9675577B2 (en) 2017-06-13
EP2976073B1 (en) 2019-08-28
KR102499654B1 (ko) 2023-02-13
BR112015024186B1 (pt) 2023-05-09
AU2014236004A1 (en) 2015-09-10
US20200268701A1 (en) 2020-08-27
WO2014153416A1 (en) 2014-09-25
BR112015024186A2 (pt) 2017-07-18
IL259502B (en) 2019-09-26
IL241316A0 (en) 2015-11-30
MX371259B (es) 2020-01-23
MX2019010248A (es) 2019-10-09
IL259502A (en) 2018-07-31
MX2015013312A (es) 2016-06-07
SG11201506780RA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
PE20151949A1 (es) Composiciones y metodos para producir cetosis elevada y sostenida
CO6761400A2 (es) Combinación de análogos de glucagón acilados con análogos de insulina
UY34091A (es) Uso de nitratos y sulfatos encapsulados para reducir la emisión de metano que se deriva de la fermentación ruminal
CR20130411A (es) Composiciones de puré que tienen proporciones de carbohidrato específicas y los métodos para utilizar las mismas
ECSP15034601A (es) Composiciones nutricionales que contienen treonato de magnesio, y sus usos
BR112014019927A8 (pt) fórmula nutricional, método de preparação da referida fórmula antes da sua ingestão por um indivíduo, uso da referida fórmula, dispositivo para prepará-la e recipiente
CL2013003144A1 (es) Composicion que comprende a) extracto de arroz fermentado con monascus purpureus, b) un acido graso omega, c) l-carnitina y uno o mas de los siguientes: d) al menos un policosanol, e) resveratrol, f) coenzima q10 y g) al menos una vitamina, util como anticolesterolemico y antitrigliceridemico y para aumentar el colesterol hdl.
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
AR091501A1 (es) Mayonesa libre de edta y metodo para su produccion
MX2015017457A (es) Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento de inflamacion.
ECSP13012799A (es) Uso de composiciones nutricionales que incluyen lactoferrinas para mejorar la resistencia a enfermedades y condiciones
BR112015027726A2 (pt) Sistema e método para tomar testemunhos de amostra congelada a partir de amostras biológicas congeladas, e, sonda de testemunhagem
BR112017013066A2 (pt) bomba peristáltica
ES2570583T3 (es) Procedimiento para el control del peso de los animales
Rivera et al. Latin@ Studies in Transnational Contexts: Reading, Writing, and Living Lives on/in the Margins
Broadwater Jr Poem titled" Home" with a recorded reading by the author, Charles E. Broadwater Jr.
Партнова PSYCHOLINGUISTIC ANALYSIS OF FAMILY AND RITUAL POETRY OF KHOINIKI REGION: HUMAN COURSE OF LIFE AS PROGRAMMING ACTIVITIES THROUGH CREATION
Valentinova “Hagiography of Avvakum, the Protopope”: On the Interpretation of Its Theological Background
Fatuschenko Boris Pasternak in the World Lyrical Tradition
袁英 et al. An Analysis of Tess the Tragic
Song et al. Silencing of FABP3 promotes mitochondrial dysfunction and apoptosis induced-cardiac abnormal development and stimulates Wnt signaling in zebrafish
李晓利 The Analysis of Stream of Consciousness in Woolf's novel Mrs. Dalloway
Malgina The “ideal middle age” of LP Karsavin: medieval history and philosophy of a history
Chistyakov The concept of personality in the novel by Vladimov “Three minutes of silence”
赖桢 Nostalgia in Michael Ondaatje's Running in the Family